Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery

NCT ID: NCT03647774

Last Updated: 2022-12-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 317 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-01
• Study Completion Date: 2022-10-13

Brief Summary

This study is designed as an open-label evaluation of how treatment with XR-NTX may influence the quality and speed of recovery of opioid dependent individuals - in a context of a naturalistic clinical treatment of opioid dependence. The study will assess recovery outcomes and compare these with the clinical effectiveness of XR-NTX (use of illicit substances and safety). Further, the study will assess the recovery outcomes in matched controls receiving treatment with buprenorphine or buprenorphine-naloxone and enrolled in the national OMT program, and compare this with participants receiving XR-NTX.

Detailed Description

This is a multicenter, open-label, treatment study of how treatment with extended-release naltrexone hydrochloride injectable suspension (Vivitrol®) (later referred to as XR-NTX) 380 mg/4 weeks will influence or promote the psycho-social recovery and somatic and psychiatric health in opioid dependent individuals. Further the study will investigate the effectiveness and safety of XR-NTX treatment given in a naturalistic setting as an alternative to OMT. The study period is 24 weeks, a subsequent 28 week follow up study and a 1 year post-treatment study. The study is composed of four"Work Packages" (WP). From the same participating sites, a control group of 150 subjects matched on age and gender and currently enrolled in the OMT program receiving daily treatment with either oral buprenorphine or buprenorphine-naloxone will be recruited. Controls will be compared with study participants on psycho-social aspects of recovery and mental and somatic health.

WP1 will use XR-NTX in a clinical naturalistic setting to describe change or improvement in recovery and in illicit drug use for this novel treatment of opioid dependent subjects. A total of n=150 participants will be recruited from five urban hospitals and community health services in Norway to receive treatment with XR-NTX. From the same hospitals and community health services we will also recruit a control group of 150 subjects matched on age and gender already enrolled in the OMT and receiving flexible dose of buprenorphine or buprenorphine-naloxone. The control group will be used for outcomes related to psycho-social recovery and health issues only. There will not be any comparison of use of illicit substances between the XR-NTX and control group. After inclusion in the study and a baseline assessment, the XR-NTX subjects will be followed-up on a monthly basis by the Principal investigator or delegated site personnel. At each visit an injection of XR-NTX will be administered and through an interview, data will be obtained on the use of heroin and other illicit substances, physical and mental health, housing and family situation, income and other social aspects. A urine or saliva sample will be obtained at every visit and screened for opioids and other illicit substances. Fertile women will in addition be screened for pregnancy. All participants will be followed up at 6 and 12 months post-treatment.

The comparison group will be assessed at baseline, after 24 weeks and after 52 weeks only. Study personnel will not administer any medication to subjects in the comparison group.

From XR-NTX participants, a saliva sample will be obtained at baseline (or at a later visit) for genetic analyses to identify possible genetic biomarkers that may predict the outcome of treatment with XR-NTX and possible markers of low catecholaminergic expression (ADHD-spectrum) Community health services from each catchment area that facilitate the recovery process involving community- and specialized health services, will be invited to participate in the study to assess the XR-NTX participants' recovery process every 4 weeks.

Controls will be assessed by the same community health services on their longer term recovery process at week 24 and at week 52.

Assessment of the descriptive elements in the participant's recovery process will be performed using brief structured interviews with the involved health-and social workers. Interviews can be done by telephone or on the net such as teleconference, if feasible.

WP 2 will use qualitative interviews to investigate the subjects' perspective on enablers and barriers to agreeing to and remaining in treatment with, a long-acting opioid receptor antagonist (XR-NTX), including possible emotional reactions and psycho-social implications of treatment. Data will be collected through a) individual semi-structured interviews with approximately 40 of the 150 XR-NTX participants: 20 subjects who stay in treatment for more than 12 weeks and 20 subjects who receive at least one injection XR-NTX but drop out before 12 weeks. In addition, individual interviews and focus group interviews, each with 6-8 close relatives of study subjects will be performed in order to investigate their conceptions regarding the recovery process of their opioid addicted family member; possible changes in familial cohesion and social relationships, and their own need for support and follow-up.

WP 3 is a health-economic study on the cost of XR-NTX treatment in study participants compared to treatment with buprenorphine or buprenorphine-naloxone (OMT) in the controls. Since the cost of medication is only one part of the total health cost of opioid dependence, we will try to estimate the total cost of health- and social services for this group of participants based on national registry data, hospital records and records from GPs and social workers. Registry-based information will be collected based on participants' personal identity number (PIN).

WP4 is designed to increase the knowledge on how opioid receptor antagonism with XR-NTX affects stress, pain and reward responses in patients. WP4 will use specifically measurements of physiological and behavioural responses to stimuli known to be modulated by the brain's opioid system such as social stressors, physical pain and rewards. In addition, data on personality and history of adverse events during childhood that may also be important predictors for adherence to treatment will be collected.

Conditions

Opioid-use Disorder

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Extended release naltrexone

Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.

Group Type: EXPERIMENTAL

Extended release naltrexone

Intervention Type: DRUG

380mg injectable extended release naltrexone every four weeks

Treatment As Usual (TAU)

Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Extended release naltrexone

380mg injectable extended release naltrexone every four weeks

Intervention Type: DRUG

Other Intervention Names

Vivitrol

Eligibility Criteria

Inclusion Criteria

-.Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.

• .Male or female at 18-65 years
• Has a current diagnosis of opioid dependence, based on the criteria of the DSM-V (304.00) as confirmed by the Mini-International Neuropsychiatric Interview (MINI)
• Is voluntarily seeking treatment for opioid dependence
• Completing a stay in a controlled environment with restricted access to substances of abuse with a minimum duration of seven days (waived for OMT controls)
• Is enrolled in the Norwegian national opioid maintenance treatment (OMT) program 'LAR' before discharge from a controlled environment. For subjects who complete & submit their LAR application while in a controlled environment, the investigator may complete enrolment data collection while awaiting response on LAR admission.
• If female and of childbearing potential, must agree to use ahighly effective method of contraception for the duration of the study (waived for OMT controls)
• Capable of understanding and complying with the study procedures

Exclusion Criteria

• Pregnancy (ie, positive urine and/or serum pregnancy test) and/or currently breastfeeding
• Clinically significant medical condition or observed abnormalities that need medical attention and follow-up (including: severe hepatic (Child-Turcotte-Pugh level C) or renal failure, clinically significant symptoms of progressive Acquired Immunodeficiency Syndrome (AIDS))
• Severe psychiatric disorder (including: current or recurrent affective disorders with suicidal behavior, psychotic disorders) that need medical attention and follow-up
• Use of any excluded medication at screening or anticipated/required use during the study period (including: requiring treatment with opioid medications other than investigational products) (waived for OMT controls)
• Known intolerance and/or hypersensitivity to XR-NTX, carboxymethylcellulose, or polylactide-co-polymers (PLG) or any other components of the diluent (waived for OMT controls).
• Alcoholism defined by the criteria in DSM V
• Serious respiratory debilitation.
• Any finding that in the view of the PI would compromise the subject's ability to fulfill the protocol visit schedule or visit requirements
• Employment by Alkermes or Reckitt-Benckiser (permanent, temporary contract worker, or designee responsible for the conduct of the study) or immediate family of an Alkermes or Reckitt-Benckiser employee.
• Abnormal laboratory assessments. If pathological values, coordinating investigator will decide if the subject is eligible for participation in the study
• Not participating in any other trial that might affect the current study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Haukeland University Hospital

OTHER

Sponsor Role: collaborator

Hospital of Southern Norway Trust

OTHER

Sponsor Role: collaborator

The Hospital of Vestfold

OTHER

Sponsor Role: collaborator

Oslo University Hospital

OTHER

Sponsor Role: collaborator

Lars Tanum

OTHER

Sponsor Role: lead

Responsible Party

Lars Tanum

Head of Research Unit, R&D dept.in Mental Health

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Lars Tanum, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Akershus

Locations

Akershus University Hospital

Loerenskog, Akershus, Norway

Countries

Norway

References

Mordal J, Juya F, Holtan L, Vederhus JK, Opheim A, Brenna IH, Enger AE, Weimand B, Solli KK, Tanum L. High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study. Addict Sci Clin Pract. 2025 Jun 16;20(1):50. doi: 10.1186/s13722-025-00576-9.

Reference Type: DERIVED

PMID: 40524244 (View on PubMed)

Marciuch A, Brenna IH, Weimand B, Solli KK, Tanum L, Rostad BK, Birkeland B. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study. Addict Sci Clin Pract. 2022 Jul 18;17(1):36. doi: 10.1186/s13722-022-00317-2.

Reference Type: DERIVED

PMID: 35850782 (View on PubMed)

Other Identifiers

269864

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2017-004706-18

Identifier Type: -

Identifier Source: org_study_id